Interv Akut Kardiol. 2020;19(3):184-186 | DOI: 10.36290/kar.2020.041

Kontroverze - aspirin po PCI?Aspirin po PCI: proč podávat

Jan F. Vojáček
I. interní kardioangiologická klinika LF UK a FN Hradec Králové

Published: September 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáček JF. Kontroverze - aspirin po PCI?Aspirin po PCI: proč podávat. Interv Akut Kardiol. 2020;19(3):184-186. doi: 10.36290/kar.2020.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011 Feb 22; 123(7): 768-78. doi: 10.1161/CIRCULATIONAHA.110.963843. Go to original source... Go to PubMed...
    2. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 2019; 40: 607-617. Go to original source... Go to PubMed...
    3. Group ASC, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529-1539. Go to original source...
    4. McNeil JJ, Wolfe R, Woods RL, et al., for ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379: 1509-1518. Go to original source...
    5. Gaziano JM, Brotons C, Coppolecchia R, et al., for ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046. Go to original source...
    6. Potpara TS, Mujovic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace. 2019 Oct 11. pii: euz259. doi: 10.1093/europace/euz259. [Epub ahead of print]. Go to original source... Go to PubMed...
    7. Windecker S, Lopes RD, Massaro T, et al. On behalf of the AUGUSTUS Investigators. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention Insights From the AUGUSTUS Trial. Circulation 140, 2019; 23: 1921-1932. Go to original source...
    8. Vranckx P, Valgimigli M, Juni P, et al. For GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392: 940-949. Go to original source...
    9. Takahashi K, Serruys PW, Chichareon P, et al. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. JACC 7 2019; 4(16): 2015-2027. Go to original source...
    10. Piccolo R, Esposito G. Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention for bifurcation lesions. Catheter Cardiovasc Interv 2020; 96: 112-113. Go to original source... Go to PubMed...
    11. Mehran R, Baber U, Sharma SK, et al. For TWILIGHT investigators. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019; 381: 2032-2042. doi: 10.1056/NEJMoa1908419. Go to original source... Go to PubMed...
    12. Hahn J-Y, Song YB, Oh J-H, et al. For SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA 2019; 321(24): 2428-2437. doi: 10.1001/jama.2019.8146. Go to original source... Go to PubMed...
    13. Watanabe H, Domei T, Morimoto T, et al. For the STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs. 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI. The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019; 321(24): 2414-2427. Published online 2019 Jun 25. doi: 10.1001/jama.2019.8145. Go to original source... Go to PubMed...
    14. Collet JP, Montalescot G, Zeitouni M. Aspirin-Free Strategies After PCI Still Not Out of the Twilight JACC 74, 2019; 16: 2028-2031. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.